Hanmi Pharmaceutical launches Efpe GLP-1 obesity treatment in South Korea

The domestic GLP-1 entry is expected to price below imported competitor drugs, per reports filed 12 October 2026.

Sarah Lindqvist-Park

Clinical Nutrition Writer

Share on X

Stands on 3 placed sources from 2 publishers.

Hanmi Pharmaceutical launches domestic obesity treatment in South Korea AI illustrationhow this picture was made

Hanmi Pharmaceutical is launching Efpe, a GLP-1 class obesity treatment, to compete in the South Korean obesity drug market.^[1] Efpe is expected to be priced in the 100,000 KRW range. This price is expected to be significantly lower than competing imported obesity treatments Wegovy and Mounjaro.^[2] Novo Nordisk submitted a health insurance coverage application for Wegovy to the South Korean Health Insurance Review and Assessment Service on 12 October 2024.^[3]

Proof3 sources · 2 publishers · signed

What this stands on

Hanmi Pharmaceutical is launching Efpe, a GLP-1 class obesity treatment, to compete in the South Korean obesity drug market. · 세계일보
Efpe is expected to be priced in the 100,000 KRW range, significantly lower than competing imported obesity treatments Wegovy and Mounjaro. · 세계일보
South Korea Novo Nordisk submitted a health insurance coverage application for obesity drug Wegovy to the Health Insurance Review and Assessment Service on 2024-10-12. · 동아일보

We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.